Table 1.

Clinical characteristics of patients according to the II-GIST Signature in the training and validation cohorts.

	Training Cohort (n = 130)				Internal Validation Cohort (n = 194)				External Validation Cohort (n = 111)
	n	High-II-GIST	Low-II-GIST	P	n	High-II-GIST	Low-II-GIST	P	n	High II-GIST	Low II-GIST	P
Median age (range)		56 (23–77)	56 (27–80)	0.542		56 (26–94)	59 (28–76)	0.934		60 (27–83)	61 (44–87)	0.070
Sex				0.229				0.707				0.803
Male	72	46	26		120	73	47		45	29	16
female	58	31	27		74	43	31		66	41	25
tumour size				0.607				0.154				0.176
≤5cm	75	43	32		109	70	39		66	45	21
>5cm	55	34	21		85	46	39		45	25	20
Primary tumour site				0.369				0.152				0.901
Stomach	82	51	31		120	67	53		75	47	28
Non-Stomach	48	26	22		74	49	25		36	23	13
Mitotic index				0.202				0.251				0.041
≤5	96	60	36		131	82	49		85	58	27
>5	34	17	17		63	34	29		26	12	14
NIH criteria				0.055				0.165				0.036
High risk	54	26	28		90	48	42		33	15	18
Intermediate risk	31	23	8		32	19	13		21	16	5
Very Low/Low risk	45	28	17		72	49	23		57	39	18
Imatinib therapy				0.478				0.362				0.264
Yes	18	12	6		20	10	10		31	17	14
No	112	65	47		174	106	69		80	53	27

Abbreviation: II, Immune-infiltration (II) based Signature; NIH, National Institutes of Health.

Mitotic index, mitoses/50 high-power field;.